Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Portman

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Menopause (New York, N.Y.)|May 7, 2015
One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophyDavid Portman, Lee Shulman, Jason Yeaw, et al.
Contraception|January 14, 2015
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pillAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Contraception|January 15, 2015
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 studyAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Obstetrics and Gynecology|January 10, 2014
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trialAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Journal of Women'S Health (2002)|February 11, 2022
Safety Profile of Bremelanotide Across the Clinical Development ProgramAnita H Clayton, Sheryl A Kingsberg, David Portman, et al.
Journal of Women'S Health (2002)|March 1, 2022
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of BremelanotideJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Obstetrics and Gynecology|October 11, 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsSheryl A Kingsberg, Anita H Clayton, David Portman, et al.
Obstetrics and Gynecology|October 11, 2019
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Menopause (New York, N.Y.)|February 26, 2015
Incremental direct and indirect costs of untreated vasomotor symptomsPhilip Sarrel, David Portman, Patrick Lefebvre, et al.
Journal of Women'S Health (2002)|December 14, 2017
A Randomized Controlled Multicenter Trial of an Investigational Liquid Nutritional Formula in Women with Cyclic Breast Pain Associated with Fibrocystic Breast ChangesRobert E Mansel, Tapas Das, Geraldine E Baggs, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Menopause (New York, N.Y.)|May 7, 2015
One-year treatment persistence with local estrogen therapy in postmenopausal women diagnosed as having vaginal atrophyDavid Portman, Lee Shulman, Jason Yeaw, et al.
Contraception|January 14, 2015
Self-reported and verified compliance in a phase 3 clinical trial of a novel low-dose contraceptive patch and pillAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Contraception|January 15, 2015
New contraceptive patch wearability assessed by investigators and participants in a randomized phase 3 studyAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Obstetrics and Gynecology|January 10, 2014
Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trialAndrew M Kaunitz, David Portman, Carolyn L Westhoff, et al.
Journal of Women'S Health (2002)|February 11, 2022
Safety Profile of Bremelanotide Across the Clinical Development ProgramAnita H Clayton, Sheryl A Kingsberg, David Portman, et al.
Journal of Women'S Health (2002)|March 1, 2022
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of BremelanotideJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Obstetrics and Gynecology|October 11, 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 TrialsSheryl A Kingsberg, Anita H Clayton, David Portman, et al.
Obstetrics and Gynecology|October 11, 2019
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderJames A Simon, Sheryl A Kingsberg, David Portman, et al.
Menopause (New York, N.Y.)|February 26, 2015
Incremental direct and indirect costs of untreated vasomotor symptomsPhilip Sarrel, David Portman, Patrick Lefebvre, et al.
Journal of Women'S Health (2002)|December 14, 2017
A Randomized Controlled Multicenter Trial of an Investigational Liquid Nutritional Formula in Women with Cyclic Breast Pain Associated with Fibrocystic Breast ChangesRobert E Mansel, Tapas Das, Geraldine E Baggs, et al.
Pageof 3